AURA
Aura Biosciences Inc
6.10$
+0.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Aura Biosciences Inc (AURA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -32 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.1 | -5.9 | -6.6 | -3.8 | -5.1 | -6.5 | -8.7 | -12 | -15 | -11 | -11 | -18 | -16 | -15 | -15 | -17 | -24 | -16 | -15 | -24 | -23 | -21 | -20 | -20 | -30 | -32 | -102 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 1.1 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.6 | 1.3 | 1.6 | 1.3 | 1.7 | 1.8 | 1.9 | 1.9 | 2.3 | 2.6 | 2.9 | 3.1 | 2.8 | 2.9 | 3.5 | 3.8 | 3.7 | 3.3 | 3.8 | 12 | 23 | |
| – | – | 0.2 | 0.2 | 0.2 | 0.3 | 0.5 | 1.3 | 1.6 | 1.2 | 1.4 | 1.2 | 1.0 | 0.8 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.6 | -0.7 | -3.4 | 0.7 | 0.4 | 1.8 | -0.6 | -2.0 | -4.3 | 1.1 | 3.3 | -3.8 | -0.5 | 2.1 | 0.8 | 2.0 | -6.8 | 1.7 | 3.4 | -0.9 | 0.4 | 2.0 | 2.0 | 1.6 | -0.4 | 1.1 | 4.2 | |
| 0.5 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.6 | 0.8 | 0.6 | 0.1 | 0.1 | 0.4 | 0.1 | 0.2 | 0.1 | 0.3 | 0.1 | 0.5 | 0.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.3 | |
| -0.5 | -0.1 | -0.1 | -0.1 | -0.1 | -0.7 | -0.6 | -0.8 | -25 | -43 | 18 | -17 | -67 | 21 | 22 | -90 | 9.4 | 20 | 9.9 | 30 | 30 | 20 | -44 | 30 | 55 | -226 | -185 | |
| – | – | – | – | – | – | – | – | 0.0 | 0.3 | 0.1 | 87 | 0.2 | 0.7 | – | – | – | – | – | – | – | – | – | – | – | -39 | – | |
| – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.1 | 4.8 | 5.1 | 87 | -0.3 | -1.1 | 80 | 0.0 | 0.3 | 0.1 | 95 | 0.2 | 2.5 | 1.6 | 93 | 0.3 | 0.1 | 0.7 | 0.5 | 0.1 | 70 | 4.4 | 2.8 | 0.3 | 462 | 469 | |
| -8.5 | -5.8 | -1.9 | 1.2 | 82 | -7.4 | -10 | 67 | -41 | -55 | 7.4 | 60 | -83 | 9.2 | 7.9 | -15 | -15 | 3.8 | -4.7 | 6.3 | 6.5 | 69 | -60 | 12 | 25 | 204 | 181 | |
| -8.6 | -5.9 | -6.7 | -3.9 | -5.2 | -7.2 | -9.3 | -13 | -16 | -11 | -11 | -18 | -17 | -15 | -15 | -18 | -25 | -17 | -16 | -24 | -24 | -21 | -20 | -21 | -30 | -32 | -103 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.